-
PhaseBio Starts Phase 2b Trial to Test PB1046 in PAH Patients
PhaseBio has started dosing its investigational compound PB1046 in patients with PAH to assess its safety, tolerability, and therapeutic activity. Click here to read more.
Are you interested in this research?
Sorry, there were no replies found.
Log in to reply.